Certified in December 2017 by INCa (National Institute of Cancer), ILIAD is one of the eight SIRICs founded on the model of integration of Comprehensive Care Centre research.
ILIAD brings together medical, scientific and technological expertise while combining different disciplines (nuclear medicine, oncology, hematology, biological sciences, human and social sciences, epidemiology, chemistry, physics and mathematics) within a consortium of 9 research laboratories, 3 health establishments and 27 high level technological platforms.
ILIAD is underpinned by integrated research, which is innovative and multidisciplinary, structured around heterogeneity and tumour resistance. Articulated around the care pathway, the research carried out by the ILIAD teams also relates to the life of the patients by integrating the issues of social inequality and how to retain a job when faced with illness.
The research programmes are represented by two tumours which have been chosen as demonstrators: multiple myeloma and breast cancer.
Presentation
The conference “Living and working with cancer” was held on Wednesday 23 November at the Cité des sciences et de l’industrie in Paris. This conference brought together more than [...]
After 5 years of research, the REWORK programme of SIRIC ILIAD is about to release a toolbox for patients with breast cancer, which includes materials to help them return to work. An achievement [...]
The annual Clarivate – Highly Cited Researchers ranking has, for the seventh consecutive year, recognised Professor Philippe Moreau, Director of SIRIC ILIAD, as a Highly Cited Researcher in [...]
On October 18th, the French PDX network and the Organoids research group organised, with the support of the SIRIC ILIAD and the CRCI²NA, a hybrid colloquium : Modeling tumor development and [...]
As part of the National Multiple Myeloma Information Day (JNM 2022) of the AF3M (Association Française des Malades du Myélome Multiple), the association has released a new information bulletin [...]
On Saturday 15 October, SIRIC ILIAD was present at the National Information Day on Multiple Myeloma (JNM 2022) of the AF3M (French Association of Multiple Myeloma Patients) in Nantes. For the [...]
What if acting on the cells surrounding the tumour could improve the effectiveness of treatments? On 14 September 2022, a team from the SIRIC ILIAD specialising in breast cancer published a [...]
The SIRIC ILIAD Partners Committee met on Monday 17 October 2022 to present the results of the 5 years of labelling. A week ago, the fifth meeting of the SIRIC ILIAD Partners Committee took place [...]